AI drug creation company Absci Corporation (NASDAQ:ABSI) shares are trading higher in premarket on Wednesday after the ...

Chip designer AMD said Wednesday that it will invest $20 million in Absci, the Vancouver company that aims to use artificial ...

Absci (ABSI) and Owkin announced a partnership bringing together two leading AI platforms to rapidly discover and design ...

The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other ...

Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop ...

Absci Corporation (ABSI), a Washington-based biotechnology company, Wednesday has announced a strategic collaboration with AMD to ...

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on AbSci (ABSI – Research Report) and keeping the price target at ...

Investors sell off AMD shares despite the company's pivot to life sciences AI, following a rating downgrade by HSBC that followed a six-month decline in the stock price.

Absci has a 52-week low of $2.45 and a 52-week high of $6.72. The firm has a market capitalization of $369.84 million, a price-to-earnings ratio of -3.46 and a beta of 2.04.

Shares of Absci on Wednesday jumped following a report on a $20 million investment from Advanced Micro Devices. The stock was up 27% to $3.89 in pre-market trading. Through Tuesday's close, shares ...

Chip designer AMD said Wednesday that it will invest $20 million in Absci, the Vancouver company that aims to use artificial intelligence to develop new drug therapies. Absci hopes artificial ...

(RTTNews) - Absci Corporation (ABSI), a Washington-based biotechnology company, Wednesday has announced a strategic collaboration with AMD to deploy AMD Instinct accelerators and ROCm software to ...